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THE EFFECTS OF PERINATAL CHOLINE SUPPLEMENTATION ON THE 
COGNITIVE FUNCTION OF THE APPNL-G-F MOUSE MODEL OF 
ALZHEIMER’S DISEASE 
 
JESSENIA YARIS LAGUNA-TORRES 
 
ABSTRACT 
Prevention of Alzheimer's disease (AD) is a major goal of biomedical sciences.  
In previous studies, this laboratory demonstrated that high intake of the essential nutrient, 
choline, during gestation ameliorated hippocampal amyloidosis in hemizygous 
APPswe/PS1dE9 (APP.PS1) AD model mice.  In this study we investigated the effects of 
a similar treatment on behavioral phenotypes in the APPNL-G-F mouse model for AD.  
These mice express a humanized APP with three mutations that cause familial AD in 
humans [Swedish (NL), Arctic (G), and Beyreuther/Iberian (F)] under the control of the 
endogenous mouse APP promotor.  The latter permits to overcome problems related to 
the overexpression of APP observed in the transgenic mouse models (e.g. APP.PS1) and 
is therefore considered a more physiological model for AD well suited for studies of the 
pathophysiology of this disease. We maintained the pregnant and lactating wild type 
C57BL/6J control mice and homozygous APPNL-G-F mice on a control AIN76A diet 
containing 1.1 g/kg of choline or a choline-supplemented (5 g/kg) diet. After weaning all 
offspring consumed the control diet. We used the male and female APPNL-G-F offspring as 
the AD model and the wild type mice as controls.  The animals were examined in a cross-
	
	 vii 
sectional fashion at 3, 6, 9 and 12 months of age using the Open Field (OF), Elevated 
Plus Maze (EPM), Barnes Maze (BM), and Contextual Fear Conditioning (CFC) 
experimental paradigms.  As compared to controls, the APPNL-G-F mice exhibited 
abnormalities in anxiety-related behaviors at 3 and 6 months of age and learning and 
memory deficits at 9 and 12 months of age. Perinatal choline supplementation 
ameliorated some of the memory deficits in the 12-month old APPNL-G-F mice observed in 
the CFC test. The data suggest that dietary supplementation with choline during fetal 
development and early postnatal life prevents some of the behavioral abnormalities in the 
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 More than a century ago, Dr. Alois Alzheimer evaluated for the first time the 
neuropathology of a patient with a rare and fast progressing paranoid condition. Her 
symptoms also included sleep, memory, and depressive problems. The neuropathology 
showed histological alterations, now known as neuritic plaques and neurofibrillary 
tangles. A couple of years later, more cases were identified with nearly exact 
symptomatology and neuropathology. Soon it started to be recognized as Alzheimer’s 
Disease (AD) after its discoverer (Hippius 2003). 
AD is the most common form of dementia affecting millions of Americans every 
year. Currently, 1 in 10 people over 65-years old have it and it’s estimated that by 2050 
there will be more than 100 million cases worldwide. AD is the sixth leading cause of 
death in the United States, and you could have it for more than 15 years before any 
clinical symptoms appear (Alzheimer’s Association 2020). During the last few decades, 
more than 400 drugs for AD, successful during preclinical studies, had failed once in the 
clinical stage (Sasaguri 2017, Nieraad 2020). This has led many scientists to focus their 
efforts on prevention rather than intervention. Some scientific groups are on focusing B-
vitamins and choline supplementation, believed to affect many mechanisms involved in 
AD pathology such as DNA methylation, Aβ and tau deposition, vascularization, 
immunity, and oxidative stress (Clarke 1998, Morris 2003, Meck 2008, Wald 2010, 
Douaud 2013, Oulhaj 2016, Strupp 2016, Grimm 2017, Huleatt 2017, Mellott 2017, 
Bruns 2019, Nieraad 2020, Velazquez 2020). For example, in a previous study 
researchers were able to prove that most of the choline in our bodies comes from our 
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diets, but most importantly, the show that a deficit in choline intake can cause liver 
damage (Zeisel 1991). Other studies with mice and rats have shown the importance of 
choline in mechanisms involved in learning and memory. For example, in our lab, 
previous studies showed that choline supplementation doesn’t alters locomotor activity in 
neither C57BL/6J WT mice or BTBR mouse model for Autism but does enhance 
exploratory behaviors and reduces anxiety using the Open Field (OF) test ( Langley 
2015). 
Choline is important in lipid metabolism and it is required for acetylcholine 
synthesis, a neurotransmitter involved in learning and memory. It is an essential nutrient 
required for normal function and health of our bodies. Interestingly, choline is neither a 
vitamin nor a mineral, although it’s very similar to vitamin B. Your liver makes it in 
small amounts which are insufficient for an optimal health (Cohen 1976, Freeman 1976, 
Blusztajn 1983, Blusztajn 1998, Zeisel 2006, Blusztajn 2013, Biswas 2015, Gonzalez 
2016, Cusick 2016, Wallace 2018, Bernhard 2019, Korsmo 2019, Derbyshire 2020). If 
liver production of choline is insufficient it’s clear that you must obtain the majority 
through your diet. The best sources of dietary choline are liver and eggs, but you can find 
good amounts in wheat germ cereal, white fish, steaks, salmon, lima beans, chicken 
breasts, and brussels sprouts, just to mention a few (VitaCholine 2016). 
Most of our brain growth and development happens in the first 1,000 days of life. 
Decreased availability of essential key nutrients can affect cell migration, proliferation, 
apoptosis, and differentiation in the developing brain. This could lead to a poor 
neurological foundation (Blusztajn 2012, González 2016, Cusick 2016, Goyal 2018, 
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Wallace 2018, Derbyshire 2020). During gestation there is a particular high demand of 
choline for adequate placental function, neurodevelopment and epigenetic programing 
(Korsmo 2019). Recent human epidemiological studies show how choline intake is also 
important in normal human development and adequate function of the central nervous 
system (Blusztajn 1998, Meck 2003, McCann 2006, Zeisel 2006). 
Previous studies from this laboratory we have shown, using APP.PS1 mouse 
model of AD, that perinatal supplementation with choline reduces some AD pathologies, 
such as Aβ40 and Aβ42 accumulation and plaque formation (Mellott 2017). APP.PS1 
mice on the choline supplemented perinatal diet showed lower levels of soluble Aβ40 and 
Aβ42 peptides as well as reduced number and size of their corresponding plaques. 
APP.PS1 females on the choline supplemented perinatal diet showed these differences at 
9 months of age, while APP.PS1 males on the choline supplemented perinatal diet 
showed them later at 12 months of age when compared to APP.PS1 mice on the control 
perinatal diet. This supports the hypothesis of how our diet and an adequate consumption 
of key nutrients involved in memory and cognition-related pathways could prevent or 
delay the onset of the neuropathological manifestations of AD (Mellott 2017, Bruns 
2019, Velazquez 2020).  
Researching preventive treatments for AD is a huge challenge because early 
symptoms are identifiable 10 to 15 years after the brain damage already began (Atria 
2019, Paquet 2020, Revi 2020). The discovery of familial AD and the genetic mutations 
associated with it combined with the ability to engineer non-natural pathologies in animal 
models, led to a whole new era in AD research. It’s important to recognize that the great 
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majority of AD cases are sporadic, but the pathologies of both sporadic and familial AD 
are similar. This allows researchers to use engineered mice with familial AD-related 
genetic mutations to understand sporadic AD (Sasaguri 2017). There are more than 205 
different mouse models for AD with different genetic mutations (Alzforum 2021). In 
most of them, the introduced mutations cause a non-physiologic APP overexpression that 
leads to unnatural symptoms and pathologies (Masude 2016). Differently from the rest, 
the APPNL-G-F mouse model for AD resembles a preclinical AD patient in which the 
aggressive amyloidosis and accumulation of microglia and activated astrocytes occurs 
way before the onset of memory impairment. 
The excessive and uncontrolled accumulation of tau and Aβ peptides inside and in 
between neurons correspondingly, interrupts neuronal communication leading to 
neuronal death. Different Aβ peptides are generated by the proteolysis of the APP protein 
by secretases. When their site of cleavage are mutates in the APP gene, it produces longer 
and less soluble Aβ peptides such as Aβ40 and Aβ42 which accumulates creating the 
famous plaques. The APPNL-G-F mice have a genetic background of a C57BL/6J with and 
endogenous APP promoter with three mutations introduced. A combination of Swedish 
(KM670/671NL), Arctic (E693G), and Beyreuther/Iberian (I716F) mutations.  
The Swedish mutation is a double point mutation close to the β-secretase site in 
APP in the positions Chr21:27269939 and Chr21:27269938. It changes codon AAG.ATG 
to AAT.CTG, resulting in the substitution of two important amino acids, lysine to 
asparagine and methionine to leucine (Mullan 1992). This double point mutation 
increases the overall production of Aβ aggregation and toxicity (Scheuner 1996, Shin 
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2010). The Artic mutation is a missense point mutation in the position Chr21:27264167. 
It changes the codon GAA to GGA, resulting in the substitution of one amino acid, 
glutamic acid to glycine (Nilsberth 2001). This missense point mutation increases 
protofibrils and resistance to neprilysin-catalyzed proteolysis of Aβ40 (Tsubuki 2003, 
Basun 2008, Nilsson 2014, Sakakibara 2018). The Iberian mutation is a missense point 
mutation in Chr21:27264098. It changed the codon ATC to TTC, resulting in the 
substitution of one amino acid, isoleucine to phenylalanine. This missense point mutation 
affects the cleavage by γ-secretase which increases dramatically the Aβ42/Aβ40 ratio 
(Lichtenthaler 1999). Taken together, these mutations cause similar clinical and 
neuropathological alterations to AD patients (Hardy 2002, Basun 2008, Nilsson 2014, 
Saito 2014, Sakakibara 2018). The APPNL-G-F mouse model for AD provides the ability to 
explore how to alter downstream cascades involved in AD.  (Bateman 2012, Ashe 2010, 
Sasaguri 2017). A more comprehensive list of the APPNL-G-F mouse model phenotype is 
displayed in Table 1. 
This study focuses on exploring how perinatal choline supplementation affects 
cognitive function in the APPNL-G-F mouse model for AD. We also collected brain 
samples for further studies exploring the nutritional effects on some mechanisms 







Table 1. APPNL-G-F Phenotype Description. 
APPNL-G-F Phenotype Description 
AD Phenotypes Definition Manifestation on APPNL-G-F 
Plaques 
Hard and highly insoluble Aβ 
accumulation clumped between neurons. 
Aggressive cortical and subcortical 
amyloidosis present. In homozygous mice 
it starts at 2 months while in heterozygous 
mice it starts at 4 months. Saturation 
achieved by 7 months. 
Tangles 
Abnormal accumulation of the tau protein 
inside neurons. 
Elevated phosphorylated tau in dystrophic 
neurites around plaques. 
Gliosis 
Changes in glial cells in response to brain 
injury. 
Accumulation of microglia and activated 
astrocytes around plaques. Starts at 2 
months. 
Synaptic Loss 
Loss of junction between neurons 
interfering with the course of important 
electrical and chemical signals. 
Reduction of immunoreactivity against 
synaptophysin and PSD95 in cortex and 
hippocampus. 
Cognitive Impairment 
Difficulty learning new things, 
remembering already learned things and 
memories, and making simple day-to-day 
decisions. 











 All animal procedures were implemented accordingly with the Animal Welfare 
Act (Assurance Number D16-00204) and the principles of the NIH Guide for the Care 
and Use of Laboratory Animals. They were also approved by the Institutional Animal 
Care and Use Committee of Boston University (Protocol #201800134). APPNL-G-F mice 
[strain C57BL/6-App<tm3(NL-G-F)Tcs>] were obtained from RIKEN BioResource 
Research Center and C57BL/6J mice were purchased from Jackson Laboratories and 
used as Wild Type (WT). Homozygous APPNL-G-F and C57BL/6J females were crossed 
correspondingly with homozygous APPNL-G-F and C57BL/6J males. Breeding pairs were 
divided into two diet groups: control and choline supplemented. Table 2 shows the 
number of subjects per genotype, perinatal diet, age, and sex. The subjects were on either 
diet from the time of breeding until the litters were weaned at postnatal day 21. Then they 
all returned to the control diet, including the offspring. Offspring were divided in a cross-
sectional way into four different age groups: 3, 6, 9, and 12 months of age. Cross-
sectional studies allow us to identify how long the effects of choline supplemented 
perinatal diet last in these mice and which is the best time to intervene for prevention. 
Control diet consisted of a standard rodent AIN76A diet (Dyets #110098) 
consisting of carbohydrates (66.00%), protein (20.30%), and fat (5.00%). This diet also 
contains sucrose (500g/kg), casein (200g/kg), starch (150g/kg), cellulose (50g/kg), corn 
oil (50g/kg), mineral mix S10001 (35g/kg), vitamin mix V10001 (10g/kg), DL-
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methionine (3g/kg), and choline chloride (1.1g/kg). Supplemented diet only differentiates 
in the choline chloride amount which is increased to 5g/kg. 
 




Mice were housed in ventilated-controlled cages with food and water as desired. 
Housing room was kept under an inverted 12-hour light/dark cycle with lights on at 22:00 
hours. Mice are naturally nocturnal mammals which means they’re awake and more 
active during the dark period (Refinetti 2004). This has been found to be beneficial for 
studies involving behavior and cognition (Beeler 2006). All behavior procedures were 
done in a testing room different from the housing room in which the lights were adjusted 
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as needed for the different behavior procedures. These behavior procedures took place in 
a window of 6 hours starting at 8:00 hours. 
 
Behavior 
A total of 263 mice were subjected to an identical schedule of behavioral 
experiments (Fig 5), starting with the least stressful which are Open Field (OF) and 
Elevated Plus Maze (EPM) following by Barnes Maze (BM) and Contextual Fear 
Conditioning (CFC). Mice were weighted before and after all behavioral tests. Their 
health status was closely monitored throughout the study. The mice were brough to the 
testing room and allowed to acclimate for 30 minutes prior to all behavioral tests. All the 
testing apparatus were sanitized with a solution containing isopropyl at 70% and allowed 
to dry in between subjects. Gloves were changed between male and female mice. 
 
Open Field Test 
 The OF test was used to evaluate general exploratory locomotion and anxiety-
related behaviors using previously described methods (Hughes 1969, Holmes 2002, 
Bailey 2009, Mellott 2014, Seibenhener 2015, Bruns 2019). The apparatus consists of a 
rectangular acrylic cage (45 x 60 x 45 cm) with high walls that prevent subjects from 
escaping (Fig 1). All trials in the OF were performed under low illumination and began 
when the mouse was placed in the back-left corner of the apparatus. All subjects were 
allowed to freely explore for a duration of 15 minutes during which the time spent within 
the center (25 x 40 cm), time spent within the border (10 cm around the perimeter), 
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average velocity, and distance traveled within the different zones were recorded. These 
data were scored using Noldus Information Technology (NIT) Ethovision 9.0 software. 
 
 
Figure 1. Open Field Testing Apparatus and Heat Map Examples. 
 
Elevated Plus Maze 
Anxiety-related behaviors were also assessed using the EPM, as described 
previously (Pellow 1985, Hogg 1996, Bailey 2009, Burke 2014, Bruns 2019). The 
apparatus consists of two open arms (30 x 10 cm) and two closed arms (30 x 10 x 46 cm) 
extending from a central area (10 x 10 cm). The entire apparatus was raised 40 cm from 
the floor (Fig 2). Each trial began when the mouse was placed in the center of the EPM 
facing an open arm. The subjects were allowed to freely explore for 5 minutes in which 
the time spent in the open arms, closed arms and central area, as well as number of 
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entries into the open arms and closed arms were recorded. Entries were scored as the 
number of times ¾ of the animal’s body entered into a given region. This was done 
manually by two to three independent viewers blind to genotype, perinatal diet, age, and 
sex. An additional score was obtained from the same previous mentioned software. All 
scores were averaged. 
 
 
Figure 2. Elevated Plus Maze Testing Apparatus and Heat Map Examples. 
 
Barnes Maze 
To evaluate visuo-spatial learning and memory, mice were trained on the BM 
(Barnes 1979, Bach 1995, Rosenfeld 2014, Bruns 2019). In this apparatus, the subjects 
learn to localize an escape hole on a circular platform measuring 92 cm of diameter and 
raised 107 cm above the floor. It contains 20 holes measuring 5 cm of diameter and 
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equally spaced 2 cm from the perimeter. A dark escape pod (10 x 10 x 8 cm) is attached 
under one of these holes, the escape hole. The apparatus was in a brightly lit testing room 
with a loud white noise played. This room also contains three different and visible extra-
maze visual cues on the walls (Fig 3). The same escape pod location was used for all 
mice and all trials. The mice were placed in the center of the maze in a black cylinder and 
the trial began when the cylinder was removed. Mice were habituated to the maze for a 2-
minute single trial and allowed to explore the maze. If they failed to find the escape hole 
by the end of the trial, they were gently guided to it. Twenty-four hours following 
habituation, mice received 3 training trials per day for 3 days (3-minutes maximum trial 
with an 18-minutes minimum intertrial interval). Here again, if they failed to find the 
escape hole after the 3-minutes trial, they were gently guided to it. Twenty-four hours 
following training, mice completed a single 30-seconds test known as the 1-day probe. 
During that test, the escape hole was covered preventing mice from escaping. During all 
trials, we measured the latency to locate the escape hole, the time to escape, the number 
or errors made (any time the subject’s nose crossed the perimeter of any hole other than 
the escape hole), the mean velocity, and the mean distance traveled. In addition, during 
the 1-day probe, total time spent in each quadrant and mean distance from hole was 
recorded. Data was scored manually by two to three independent viewers blind to 
genotype, perinatal diet, age, and sex. An additional score was obtained from the same 







            Figure 3. Barnes Maze Testing Apparatus and Heat Map Examples. 
 
Contextual Fear Conditioning 
The CFC was performed following a modified protocol described previously 
(Wiltgen 2005, Pham 2008, Zuloaga 2016, Mehla, 2019). CFC is used to assess learning 
and both amygdala- and hippocampus-dependent memory. The testing apparatus 
consisted of an acrylic cage (17 x 17 x 25 cm) with four walls, no top or base. 
MazeEngineers Fear Conditioning Chamber integrated with the same previous mentioned 
software. It contains a fixed video recording camera on the top. The floor of the cage 
consisted of a removable grid with rods with a diameter of 4 mm spaced 5 mm from each 
other. The rods were connected to a shock generator with a current range from 0.1 to 4.0 
mA in 0.1 mA steps. The cage was inside an isolation cubicle containing speakers used to 
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deliver the tone stimulus. Different acrylic contextual plates (white vs vertical stripes) 
were used to allow for contextual learning (Fig 4). 
The mice were placed in the conditioning chamber with white plates (context 1). 
Mice were subjected to five consecutive conditioning trials, each separated by a 2-
minutes intertrial interval. Five 20-seconds tones at 2000 Hz with an electric shock (2 
seconds, 0.5 mA) during the last 2 seconds of the tone duration were given after a 2-
minutes baseline. All subjects received five conditioning trials, each separated by a 2-
minutes intertrial interval. Mice were taken from the conditioning chamber (context 1, 
Fig 4) 1-minute after the last shock and returned to their home cages. Twenty-four hours 
later, the mice were placed in the same chamber but with different stripes plates (context 
2, Fig 4) for the tone test. Five 20-seconds tones were given after a 2-minutes baseline 
period. Each tone presentation was separated by a 2-minutes intertrial interval. The 
murine fear response to the tone in anticipation of the shock is immobility or “freezing”. 
Twenty-four hours after the tone test, all subjects were placed back in the same chamber 
with the white plates (context 1, Fig 4) for a 5-minutes context test. The freezing 




Figure 4. Context Fear Conditioning Testing Apparatus. 
 
Brain Extraction and Dissection 
Upon euthanasia by CO2 inhalation, 1 week after all behavior tests were done, we 
dissected all subjects’ brains. The right hemispheres of all brains were fixed in PLP 
fixative [4% (vol/vol) paraformaldehyde, 75mM lysine, 10mM sodium periodate; pH 7.4] 
at 4 degrees overnight and cryoprotected using 10% (vol/vol) and 20% (vol/vol) glycerol 
/ 2% (vol/vol) dimethyl sulfoxide in 0.1 M PBS, pH 7.3, for twenty-four hours each. 
While the left hemispheres were immediately dissected and samples for protein, DNA, 
and RNA from the prefrontal cortex, striatum, and hippocampus were collected and 
frozen at -80 degrees C. Right hemispheres were stored for future immunohistochemistry 
studies, while left hemispheres were stored for future DNA methylation analyses. Figure 




Figure 5. Methodology Timeline Diagram. 
 
Statistical Analyses 
 Data is presented as mean ± SEM. Statistical differences between genotype, 
perinatal diet, and sex against the behavioral parameters were determined by repeated-
measures multivariate analysis of variance (MANOVA). When differences in sex were 
not significant, we created a data sub-set excluding the sex variable. In this data sub-set, 
statistical differences between genotype and perinatal diet against the behavioral 
parameters were determined by repeated-measures MANOVA. To determine the 
variability and significance of differences within each repeated-measure, we created data 
sub-sets including only the data of interest and performed t-test analysis. When no 
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repeated-measures were present, t-test analysis were also performed. All statistical 
























 Here we tested the if choline perinatal supplementation has any effects on the 
cognitive function of WT and APPNL-G-F mice at different age groups (3, 6, 9, and 12 
months of age). As described in the methods section, we used OF, EPM, BM, and CFC. 
Weight was recorded before and after testing. The mice’s health was closely monitored, 
and every pathology was recorded as well as litters lost during the breeding process. 
Differences found between male and female subjects are presented when significant. 
 
Open Field 
The OF test was used to assess general exploratory locomotion and anxiety levels, 
shown by the avoidance of the center, using previously described methods (Hughes 1969, 
Holmes 2002, Bailey 2009, Mellott 2014, Seibenhener 2015, Bruns 2019). In general, 
mice initially spend more time and travel more in the border at the start the test. As the 
test continues, mice typically increase their exploration of the center of the OF apparatus. 
We observe this behavior in all groups of mice suggesting normal locomotor and 
exploratory behavior in the OF. However, we did observe differences between specific 
groups of mice at different ages.  
At 3 months of age, APPNL-G-F mice on the control perinatal diet spent more time 
within the center of the arena (p-value=0.0075, Fig 10A) at lower velocities (p-
value=0.0084, Fig 8A) than the rest of the mice. In contrast, when given a choline 
supplemented perinatal diet, they spent similar time within the center of the arena (Fig 
10A) at similar velocity (Fig 8A) than WT mice regardless of diet. This indicates that 
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increased dietary choline during early development normalizes the behavior of APPNL-G-F 
mice in such a way that they behave like WT mice at 3-months of age. At 6 months of 
age, all mice behave similarly regardless of genotype or perinatal diet (Figs 6B-11B). 
These results are consistent with previous studies where APPNL-G-F males do not show 
different levels of locomotor activity or anxiety than WT in the OF (Saito 2018, Whyte 
2018).  
At 9 months of age, APPNL-G-F mice on the control perinatal diet traveled less 
distance (p-value=0.0364, Fig 6C) at faster velocity (p-value=0.0012, Fig 8C) and spent 
less time (p-value=0.0424, Fig 10C) within the center of the arena than the rest of the 
mice. In contrast, they traveled increased distance (p-value=0.0004, Fig 7C) at lower 
velocity (p-value=0.0003, Fig 9C) and spent increased time (p-value=0.0426, Fig 11C) at 
the borders of the arena than the rest of the mice regardless of genotype and diet. 
Interestingly, APPNL-G-F mice on the choline supplemented perinatal diet behave similar 
to their WT counterparts regardless of diet. This indicates that increased dietary choline 
during early development normalizes the behavior of APPNL-G-F mice in such a way that 
they behave like WT mice at 9-months of age . The effects of perinatal choline 
supplementation are no longer present in 12-months old APPNL-G-F mice while differences 
between APPNL-G-F mice  and WT remained (Figs 6D-11D). This suggests that the 





Figure 6. Distance Traveled in the Center of the OF. OF test was performed to mice in 
different age groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months of age, and 
(D) 12 months of age. Distance traveled in the center of the arena was recorded 
throughout a 15-minute trial and presented over 5-minute intervals. Significant effects of 
perinatal diet and genotype on the distance traveled in the center of the arena are 




Figure 7. Distance Traveled in the Border of the OF. OF test was performed to mice in 
different age groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months of age, and 
(D) 12 months of age. Distance traveled in the border of the arena was recorded 
throughout a 15-minute trial and presented over 5-minute intervals. Significant effects of 
perinatal diet and genotype on the distance traveled in the border of the arena are 





Figure 8. Mean Velocity in the Center of the OF. OF test was performed to mice in 
different age groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months of age, and 
(D) 12 months of age. Mean velocity in the center of the arena was recorded throughout a 
15-minute trial and presented over 5-minute intervals. Significant effects of perinatal diet 





Figure 9. Mean Velocity in the Border of the OF. OF test was performed to mice in 
different age groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months of age, and 
(D) 12 months of age. Mean velocity in the border of the arena was recorded throughout 
a 15-minute trial and presented over 5-minute intervals. Significant effects of perinatal 






Figure 10. Time Spent in the Center of the OF. OF test was performed to mice in 
different age groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months of age, and 
(D) 12 months of age. Time spent in the center of the arena was recorded throughout a 
15-minute trial and presented over 5-minute intervals. Significant effects of perinatal diet 






Figure 11. Time Spent in the Border of the OF. OF test was performed to mice in 
different age groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months of age, and 
(D) 12 months of age. Time spent in the border of the arena was recorded throughout a 
15-minute trial and presented over 5-minute intervals. Significant effects of perinatal diet 




Elevated Plus Maze 
The EPM test was used to measure anxiety levels shown by avoidance to the open 
arms using previously described methods (Pellow 1985, Hogg 1996, Bailey 2009, Burke 
2014, Bruns 2019). Typically, mice will spend more time in the closed arms than the 
open arms during the EPM. Any changes in time in open arms is indicative of alterations 
in the level of anxiety of the mice (Bourin 2015, Carobrez 2015). In previous studies, 
APPNL-G-F males showed anxiolytic behaviors when compared to APPNL-F as shown by 
increased exploration of the open arms (Sakakibara 2018). 
Time spent in (Fig 12) or number of entries into (Fig 13) the different arms as 
well as the percent of entries into the open arms (Fig 14) of the EPM showed no 
significant effects of perinatal diet or genotype overall. Interestingly, when only females 
are assessed, there are significant differences. At 3 months of age, WT females on 
choline supplemented perinatal diet spent increased time in the open arms (p-
value=0.0300, Fig 15A), spent decreased time in the closed arms (p-value=0.0019, Fig 
15A), and have a higher percent of entries into the open arms (p-value=0.0029, Fig 15C) 
than WT females on the control perinatal diet. While these effects are more significant in 
WT females than in APPNL-G-F females, both genotypes are influenced by increased 
choline availability. 
At 6 months of age, APPNL-G-F females on the control perinatal diet spent decreased time 
in the open arms (p-value=0.0483, Fig 15B), spent increased time in the closed arms (Fig 
15B), and had a lower percent of entries into the open arms (p-value=0.0178, Fig 15D) 
than the rest. APPNL-G-F females on the choline supplemented perinatal diet showed 
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increased time spent in the open arms (Fig 15B), decreased time spent in the closed arms 
(Fig 15B), and a higher percent of entries into the open arms (p-value=0.0290, Fig 15D) 
than the APPNL-G-F females on the control perinatal diet and similar to WT mice. This 
indicates that increased dietary choline during early development normalizes the behavior 
of APPNL-G-F females in such a way that they behave like WT mice at 6-months of age. 
These results are consistent with perinatal choline supplementation decreasing anxiety in 
young WT and BTBR T+Itpr3tf/J (BTBR) mice, a mouse model of autism. In addition, 
these results suggest that the severity of AD in APPNL-G-F mice (especially in males) 
outweighs the effects of perinatal choline supplementation in the EPM. 
 
 
Figure 12. Time Spent in the Different Arms of the EPM. EPM test was performed to 
mice in different age groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months of 
age, and (D) 12 months of age. Time spent in the different arms was recorded throughout 
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a 5-minute trial. No significant effects of diet or genotype on time spent in the different 
arms were found as determined by t-test. 
 
 
Figure 13. Entries to the Different Arms of the EPM. EPM test was performed to mice in 
different age groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months of age, and 
(D) 12 months of age. Entries to the different arms was recorded throughout a 5-minute 
trial. Significant effects of diet and genotype on entries to the different arms are indicated 




Figure 14. Percent of Entries to the Open Arms of the EPM. EPM test was performed to 
mice in different age groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months of 
age, and (D) 12 months of age. Percent of entries to the open arms was calculated 
throughout a 5-minute trial. No significant effects of diet or genotype on time spent in the 




Figure 15. Time Spent in the Different Arms Compared to Percent of Entries to the Open 
Arms of the EPM by Females. Time spent in the different arms was recorded for 3 
months-old (A) and 6 months-old (B) females. Percent of entries to the open arms was 
calculated for 3 months-old (C) and 6 months-old (D) females. Significant effects of diet 
and genotype on both times spent in the different arms and percent of entries to the open 









The BM allows us to evaluate visuo-spatial learning and memory (Barnes 1979, 
Bach 1995, Rosenfeld 2014) as shown by mice ability to learn to locate an escape hole on 
a circular platform using spatial cues (Fig 3). This task is known to be hippocampal-
dependent (Harrison 2006, Sharma 2010, Sakakibara 2018) and is frequently used to 
evaluate memory deficits in AD mice (Reiserer 2007, O’Leary 2009, Yassine 2013, 
Sakakibara 2018). The latency to locate the escape hole, the total time to escape, the 
number of errors made, the distance traveled, and the mean velocity were recorded in all 
training trials. In addition, the time spent in each quadrant was recorded during the probe 
trial.  
In previous studies, 6 months old APPNL-G-F mice have been shown to display 
intact spatial memory while 8 months old APPNL-G-F mice exhibit reduced spatial learning 
with normal spatial memory (Sakakibara 2018). Here, mice in all groups (perinatal diets, 
genotypes, and ages) showed a reduction in latency to find the hole (Fig 16), a reduction 
in latency to escape (Fig 17), and a reduction in number of errors made (Fig 18), from 
day 1 to day 3. This indicates that they were able to learn the task appropriately. The only 
exception to this were 12-months old APPNL-G-F mice which showed little to no 
improvement in mean latency to hole (p-value=0.0176, Fig 16D) as well as in number of 
errors made (Fig 18D) from day 1 to 3. Indicating that their learning performance was 
impaired, different than WT. 
After 3 days of training, we performed the 1-day probe. When measuring the time 
spent in each quadrant, mice in all age groups behaved differently (Fig 21). At 3 months 
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of age, APPNL-G-F mice in the control perinatal diet spent less time in the target quadrant 
than their WT counterparts while APPNL-G-F mice in the choline supplemented perinatal 
diet spent more time in the target quadrant similar to their WT counterparts regardless of 
diet (Fig 21A).  At 6 months of age, these differences disappear across all groups (Fig 
21B), and all mice regardless of genotype and dietary group behaved similarly. At 9 
months of age, WT mice in choline supplemented perinatal diet group spent less time in 
the target quadrant than the WT in control perinatal diet and than their APPNL-G-F 
counterparts regardless of diet. In addition, they spent similar time in every quadrant (Fig 
21C). Surprisingly, they made fewer errors than the WT mice in the control perinatal diet 
group (p-value=0.0459, Fig 23C). At 12 month of age WT mice in control perinatal diet 
group spent the same time in every quadrant (Fig 21D) but still found the hole faster than 
their APPNL-G-F counterparts regardless of diet (Fig 22D). This suggests that even though 
they find the target faster, they continue exploring the maze. On the other hand, 12 month 
of age WT mice in supplemented perinatal diet not only spent more time in the target 
quadrant than the rest (p-value=0.0011, Fig 21D) but also found the hole faster than the 
rest (Fig 22D). 
At 9 months of age, WT mice on control perinatal diet showed higher number of 
errors (Fig 23C) but interestingly found the hole faster (Fig 22C) than their APPNL-G-F 
counterparts regardless of diet. At 9 months of age WT mice on choline supplemented 
perinatal diet had lower number of errors than those on control perinatal diet (Fig 23C) 
even though no difference on latency to hole was found (Fig 22C). At 12 months of age 
WT mice on choline supplemented diet had lower number of errors (Fig 23D) and found 
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the hole faster than the rest (Fig 22D). These data suggests that choline supplementation 
improves spatial memory in WT mice. 
 
 
Figure 16. Mean Latency to Hole in the BM. BM test was performed to mice in different 
age groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months of age, and (D) 12 
months of age. Total time required to localize the target hole was recorded per trial and 
average per day of training per animal. Mean latency to hole of the BM is represented 
over the habituation and 3 days of training. Significant effects of diet and genotype on 





Figure 17. Mean Latency to Escape in the BM. BM test was performed to mice in 
different age groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months of age, and 
(D) 12 months of age. Total time required to escape into the target hole was recorded per 
trial and average per day of training per animal. Mean latency to escape of the BM are 
represented over the habituation and 3 days of training. Significant effects of genotype on 






Figure 18. Mean Number of Errors in the BM. BM test was performed to mice in 
different age groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months of age, and 
(D) 12 months of age. Total number of errors before identifying the target hole was 
recorded per trial and average per day of training per animal. Mean number of errors in 
the BM are represented over the habituation and 3 days of training. Significant effects of 






Figure 19. Mean Distance Traveled in the BM. BM test was performed to mice in 
different age groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months of age, and 
(D) 12 months of age. Total distance traveled was recorded per trial and average per day 
of training per animal. Mean distance traveled in the BM are represented over the 
habituation and 3 days of training. Significant effects of diet and genotype on mean 






Figure 20. Mean Velocity in the BM. BM test was performed to mice in different age 
groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months of age, and (D) 12 
months of age. The velocity was recorded per trial and average per day of training per 
animal. Mean velocity in the BM are represented over the habituation and 3 days of 
training. Significant effects of diet and genotype on mean velocity are indicated as 






Figure 21. Time Spent in the Quadrants on the 1-DP in the BM. BM test was performed 
to mice in different age groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months 
of age, and (D) 12 months of age. Time spent in the quadrants was recorded during the 30 
s of the 1-DP. Time spent in the target, opposite, left adjacent, and right adjacent 
quadrants on the 1-DP of the BM are represented. The black horizontal line indicates the 
time in a quadrant expected by chance (7.5s). * = time significantly greater than chance 
(p < 0.05) with a t-test. O = time significantly different from the opposite quadrant, L = 
time significantly different from the left adjacent quadrant, R = time significantly 





Figure 22. Mean Latency to Hole on the 1-DP in the BM. BM test was performed to mice 
in different age groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months of age, 
and (D) 12 months of age. Total time required to localize the target hole was recorded 
during the 30 s of the 1-DP and average per testing group. Significant effects of genotype 







Figure 23. Mean Number of Errors on the 1-DP in the BM. BM test was performed to 
mice in different age groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months of 
age, and (D) 12 months of age. Total number of errors before identifying the target hole 
was recorded during the 30 s of the 1-DP and average per testing group. Significant 









Figure 24. Mean Distance from Hole on the 1-DP in the BM. BM test was performed to 
mice in different age groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months of 
age, and (D) 12 months of age. Significant effects of diet on mean distance from hole are 
indicated as determined by t-test. 
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Contextual Fear Conditioning 
CFC was performed to address both hippocampal- and amygdala-dependent 
memories using induced learned fear (Selden 1990, Phillips 1992, Maren 1998, Shakibara 
2018). The learning and memory mechanisms involved in conditioned fear responses are 
impaired in both human AD patients and mouse models of AD (Hamann 2002, Hoefer 
2008) and mouse models of AD (Dineley 2002, Reiserer 2007, Knafo 2009, O’Leary 
2009, Yassine 2013, Sakakibara 2018).  
CFC consists of one day of conditioning followed by two days of tone and context 
test respectively. On day 1, the mice were placed in the conditioning chamber with 
context 1 for conditioning. On day 2, the mice were placed in the same chamber but with 
a different context (context 2, Fig 4) to assess the tone test which is known to be 
amygdala dependent. On day 3, the mice were placed back in the same chamber with 
context 1 to assess the context test which is known to be hippocampal-dependent. In 
previous studies, APPNL-G-F mice up to 18 months of age, showed no significant deficits 
in learning and memory in the CFC (Sakakibara 2018). It is important to be aware that 
the majority of studies using APPNL-G-F mice only test male subjects. Here we used both 
male and female APPNL-G-F and WT mice. 
On day 1 (conditioning), 3-, 6-, and 9-months old mice in all groups, including 
both perinatal diets and both genotypes, showed an increase in percent of freezing from 
trial 1 to 5 (Figs 25A-25C). At 9 months of age, APPNL-G-F mice in the control perinatal 
diet group show less freezing than their WT counterparts in both tone test (p-
value=0.0044, Fig 26C) and context test (Fig 26C). This impairment in memory is 
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rescued by perinatal supplementation of APPNL-G-F mice at this age in such a way that the 
APPNL-G-F mice behave like WT mice. Only 12 months APPNL-G-F mice showed both 
impaired learning (p-value=0.0001, Fig 25D) and impaired memory (Fig 26D). At 12 
months of age, APPNL-G-F mice in the control perinatal diet show impairments in both the 
tone (Fig 26D) and context tests (p-value=0.0120, Fig 26D). The severity of AD in 
APPNL-G-F mice outweighs the effects of perinatal choline supplementation in the CFC at 
this age. 
In contrast to previous studies in which they failed to detect any significant 
impairment of APPNL-G-F mice on the CFC (Sakakibara 2020), our data show that 9 
months old APPNL-G-F mice have intact learning ability (Fig 25C) but impaired amygdala- 
and hippocampal-dependent memory as shown by reduced freezing during both tone test 
(p-value=0.0044, Fig 26C) and context test (Fig 26C). In addition, 12 months old APPNL-
G-F mice have a significant impairment in both learning (p-value=0.0001, Fig 25D) and 
amygdala- and hippocampal-dependent memory (Fig 26D). 
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Figure 25. Percent of Freezing on Conditioning Day in the CFC. CFC test was performed 
to mice in different age groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months 
of age, and (D) 12 months of age. Total time spent frozen was recorded throughout a 12-
minute conditioning and percent of freezing was calculated and averaged per testing 
group. Significant effects of perinatal diet and genotype on percent of freezing are 




Figure 26. Average Percent of Freezing on the Tone Test Compared with Average 
Percent of Freezing on the Context Test. Tone and Context tests were performed to mice 
in different age groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months of age, 
and (D) 12 months of age. Total time spent frozen was recorded throughout a 12-minute 
tone test and 4-minute context test respectively. Percent of freezing was calculated and 
averaged per testing group. Significant effects of perinatal diet and genotype on percent 
of freezing are indicated as determined by MANOVA. 
 
Figure 45. .......Average Percent of Freezing on 
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Weight and Identified Pathologies 
Besides emotional and memory disturbances, AD patients show changes in 
weight, skin condition, and seizures. To address these additional pathologies, mice were 
weighed before and after all behavioral tests were done. Their health status was closely 
monitored throughout the study as well. Previous studies with APPNL-G-F mice showed 
contradicting results in this matter. Some groups showed no effect of genotype on weight 
when comparing APPNL-G-F mice with WT mice (Kundu 2021). Other groups showed that 
APPNL-G-F mice were consistently heavier than WT mice up to 26 weeks of age (Whyte 
2018). Here we showed no significant effect of genotype or perinatal diet on weight in 
neither APPNL-G-F mice or WT mice (Fig 27). 
Some of the pathologies identifies are small size at birth known as runts, seizures, 
skin-related conditions such as ulcerative dermatitis and alopecia areata, eye-related 
problems such as retinal vein occlusion, curly tails (sometimes due to neural tube 
defects), poor body condition such as hunched-backs, bloody brains due to broken brain 
vessels and capillaries, early death due to natural causes or required early euthanasia 
because of poor health condition, and enlarged organs detected at euthanasia. 
Throughout the study we were able to identify some pathologies which present 
differently in male and female subjects. At 3 months of age (Fig 28A), 14.29% of APPNL-
G-F males on the control perinatal diet presented eye-related problems and 10.00% of 
APPNL-G-F males on the choline supplemented perinatal diet presented skin-related 
problems. At 6 months of age (Fig 28B), 20.00% of APPNL-G-F males on the control 
perinatal diet were runts at birth, 20.00% of the APPNL-G-F males on the control perinatal 
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diet and 8.33% of WT males on the supplemented perinatal diet presented skin-related 
problems, 8.33% of WT males on the choline supplemented perinatal diet presented 
hunched backs, other 8.33% presented bloody brains at brain extraction, and other 8.33% 
were found dead before behavioral tests were performed. At 9 months of age (Fig 28C), 
12.50% of WT males on the control perinatal diet presented bloody brain at brain 
extraction and 66.67% of APPNL-G-F males on the control perinatal diet presented seizures. 
At 12 months of age (Fig 28D), 28.57% of APPNL-G-F males on the control perinatal diet 
were runts at birth, other 28.57% presented seizures, and other 42.86% presented skin-
related problems, 10.00% of WT on the control perinatal diet and 50.00% of WT on the 
choline supplemented perinatal diet presented skin- related problems. 
At 3 months of age (Fig 29A), 28.57% of WT females on the choline 
supplemented perinatal diet presented skin-related problems and other 28.57% presented 
hunched backs, 12.50% of APPNL-G-F females on the control perinatal diet presented skin-
related problems, 11.11% of APPNL-G-F females on the choline supplemented perinatal 
diet were runts at birth, other 11.11% presented skin-related problems, and other 11.11% 
presented curly tails. At 6 months of age (Fig 29B), 7.69% of WT females on the control 
perinatal diet presented skin-related problems and other 7.69% were sacrificed before 
behavioral tests were performed, 16.67% of APPNL-G-F females on the control perinatal 
diet presented hunched backs. At 9 months of age (Fig 29C), 22.22% of WT females on 
the control perinatal diet presented skin-related problems, other 11.11% were sacrificed 
before behavioral testing were performed and other 11.11% presented enlarged organs at 
brain extraction, 50.00% of WT females on choline supplemented perinatal diet presented 
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skin-related problems and other 12.50% presented enlarged organs at brain extraction, 
25.00% of APPNL-G-F females on the control perinatal diet presented hunched backs, 
12.50% of APPNL-G-F females on the choline supplemented perinatal diet presented eye-
related problems and other 12.50% presented bloody brains at brain extraction. At 12 
months of age (Fig 29D), 12.50% of WT females on choline supplemented perinatal diet 
were runts at birth, 16.67% of APPNL-G-F females on control perinatal diet were found 
dead before the behavioral studies were performed, and 11.11% of APPNL-G-F females on 
the choline supplemented perinatal diet presented skin-related problems. 
Finally, it’s important to mention the high mortality rate of the APPNL-G-F mice on 
the control perinatal diet compared to the rest. While breeding, we lost 16 litters (53%) 
from the APPNL-G-F mice on the control perinatal diet compared to 13 litters (44%) from 
the WT on the control perinatal diet, 8 litters (44%) from the WT mice on the choline 
supplemented perinatal diet, and 10 litters (42%) from the APPNL-G-F mice on the choline 




Figure 27. Weight and Weight Change. Weight was recorded the first and last days of 
behavioral testing for both males and females from different age groups: 3 months of age, 
6 months of age, 9 months of age, and 12 months of age and average per testing group. 
Initial weight for males (A) and females (B) as well as weight change in males (C) and 
females (D) in all age groups is shown. Significant effect of age, genotype and diet on 





Figure 28. Pathologies Identified in Males. Health status was closely monitored 
throughout the study and all identified pathologies were recorded from males in different 
age groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months of age, and (D) 12 




Figure 29. Pathologies Identified in Females. Health status was closely monitored 
throughout the study and all identified pathologies were recorded from females in 
different age groups: (A) 3 months of age, (B) 6 months of age, (C) 9 months of age, and 
(D) 12 months of age and average per testing group. 
 
 
Figure 30. Number and Percent of Dead Litters. (A) Total number of litters was recorded 





 We have shown that APPNL-G-F mice exhibit changes in anxiety-related behaviors 
seen as early as 3 and 6 months of age while learning and memory alterations have a later 
onset starting at 9 months of age and evident by 12 months of age. This is consistent with 
the time in which Aβ amyloidosis starts saturating the hippocampus and subcortical 
regions (Saito 2014, Sakakibara 2018). Interestingly, intense neuroinflammatory 
responses such as astrocytes and microgliosis are not identifiable until APPNL-G-F mice 
reach the age of 15 months old (Masuda 2016, Sakakibara 2018). As mentioned 
previously, the combination of knocked-in mutations present in APPNL-G-F mice produces 
an AD mouse model that presents the pathological Aβ and tau alterations before the onset 
of cognitive impairment similar to what happens in AD patients providing the ability to 
explore downstream cascades involved in AD. Here we showed how perinatal choline 
supplementation delays some of these impairments in APPNL-G-F mice. 
To address general exploratory locomotion and anxiety-related behaviors we 
performed OF and EPM. Increased availability of choline during early development 
produces a normalization in anxiety-related behaviors in APPNL-G-F mice at 3- and 9-
months of age as shown in the OF. At 12-months of age, the severity of AD in APPNL-G-F 
mice outweighs the effect of perinatal choline supplementation. These effects were not 
seen in the EPM. We show that when females are analyzed apart in the EPM, the 
perinatal choline supplementation produces a normalization of anxiety-related behaviors 
in APPNL-G-F mice at 3- and 9-months of age. Increased availability of choline early in 
development in APPNL-G-F females seems similar to the effects of an anxiolytic treatment 
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in WT mice as shown on the EPM (Handley 1984, Gonzalez 1997, Rodgers 1997, Bailey 
2009). 
EPM results are presented differently between research groups, as increased time 
in the open arms is seen as both reduced anxiety and increased anxiolytic-behavior, 
which means the same. It’s important to understand that in this task decreased time in the 
open arms which translates into increased anxiety levels, is the natural and expected 
response of a normal mice. Interestingly, when you provide WT mice with some kind of 
anxiolytic treatment, their anxiety levels decrease, and they tend to explore more the open 
arms without affecting any other type of behavior (Pellow 1986, Rodgers 1997, Bertoglio 
2002, Holmes 2003, Crawley 2007, Bailey 2009). Some studies with APP.PS1 mice 
show increased time spent in the open arms as evidence of reduced anxiety levels 
compared to their WT counterparts (Lalonde 2004, Reiserer 2007). 
To address visuo-spatial learning and memory alterations we performed BM and 
CFC. We showed that APPNL-G-F mice start presenting visuo-spatial learning impairments 
at 9 months of age which worsen at 12 months of age affecting also memory. Choline 
perinatal supplementation salvage age-related visuo-spatial learning and memory deficits 
in WT mice as shown in the BM. We also showed that APPNL-G-F mice start presenting 
impaired amygdala- and hippocampal-dependent memory without impaired learning 
ability at 9 months of age as shown in the CFC. This impairment in memory is rescued by 
choline perinatal supplementation in such a way that APPNL-G-F mice behave like WT 
mice. At 12 months of age, APPNL-G-F mice showed impairments in learning, amygdala- 
and hippocampal-dependent memory. At this age, the severity of AD in APPNL-G-F mice 
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outweighs the effect of perinatal choline supplementation on visuo-spatial learning and 
memory as well as on amygdala- and hippocampal-dependent memory. 
 AD patients show emotional and memory disturbances but also changes in 
weight, skin condition, and even seizures at late stages of the disease. In fact, AD patients 
have approximately a 10 times higher risk of developing seizures than healthy individuals 
of the same age (Mendez 2003, Scarmeas 2009, Pandis 2012, Chen 2017, Aguirre 2019). 
We didn’t find significant differences in weight between APPNL-G-F mice and WT mice in 
either diets. But we were able to detect some pathologies that were presented in more 
APPNL-G-F subjects than in WT subjects starting at 3 months of age. Some of these are 
eye-related problems, skin-related problems, runts at birth, hunched backs, and bloody 
brains at brain extraction. 
There were two pathologies that capture our attention more than the rest. The first 
was the fact that APPNL-G-F mice on the control perinatal diet had a higher rate of 
mortality at birth, losing approximately 10% more of the litters before they even reached 
3 days old. To prevent the loss of litters due to neglect by new mothers, we used helper 
mothers of the same dietary group and genotype that previously had successful litters, but 
no differences in litter viability were observed. The second was the occurrence of 
seizures starting at 9 months of age. This was present exclusively in APPNL-G-F males on 
the control perinatal diet, suggesting that choline supplemented perinatal diet could be 
protecting the brain of APPNL-G-F mice from such disturbances. The presence of seizures 
in only male mice also suggests increased vulnerability to AD in these mice. 
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Taken together, these findings support previous studies in which increased dietary 
choline during early development has lasting beneficial effects on behavior. Importantly, 
we showed that in APPNL-G-F mice, perinatal choline supplementation is capable of 
delaying the onset of AD-related behaviors and pathologies. The severity of AD in 
APPNL-G-F mice at 12-months of age outweighs the beneficial effects of choline perinatal 
supplementation, suggesting that by this age the brain damage is already irreversible. 
Further studies investigating the effects of choline dietary supplementation for longer 
time, passed the perinatal period, on APPNL-G-F mice, could provide valuable information 
on the importance of dietary choline intake for the prevention or delaying of AD-related 
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